Experiment Number: 20614 - 01 Test Type: CHRONIC Route: DOSED FEED Species/Strain: RATS/HSD	P10: STATISTICAI	L ANALYSIS OF NON-NEOPLASTIC LESIONS Perfluorooctanoic Acid CAS Number: 335-67-1	Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT
	Uterine section r	eport with litter 0-300, 150-300	
NTP Study Number:	C20614		
Lock Date:	01/10/2012		
Cage Range:	ALL		
Date Range:	ALL		
Reasons For Removal:	25021 TSAC	25020 NATD	25019 MSAC
	25016 Aborted		
Removal Date Range:	ALL		
Treatment Groups:	Include 004 0/300 ppm	Include 006 150/300 ppm	
Study Gender:	Both		
TDMSE Version:	2.5.0.0_SFH		
PWG Approval Date:	07/25/2018		

Experiment Number: 20614 - 01 Test Type: CHRONIC Route: DOSED FEED Species/Strain: RATS/HSD

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Perfluorooctanoic Acid CAS Number: 335-67-1 Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PERFLUOROOCTANOIC ACID

FEMALE RATS

Organ

Vagina (Longitudinal Evaluation) Vagina (Standard or Longitudinal Evaluation)

Morphology

Hyperplasia, Granular Cell Hyperplasia, Granular Cell

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus (Longitudinal Evalua Adenomyosis	ation)	
LESION RATES		
OVERALL (a)	3/49 (6%)	1/50 (2%)
LITTERS (b)	3/29 (10%)	1/29 (3%)
POLY-3 RATE (c)	3/40.88	1/41.44
POLY-3 PERCENT (g)	7.3%	2.4%
TERMINAL (d)	3/27 (11%)	1/32 (3%)
FIRST INCIDENCE	744 (T)	744 (T)
STATISTICAL TESTS		
POLY 3		P=0.300N
POLY 1.5		P=0.303N
POLY 6		P=0.289N
RAO-SCOTT		P=0.326N
LITTER C-A/FISHERS		P=0.306N

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus (Standard or Longitı Adenomyosis	udinal Evaluation)	
LESION RATES		
OVERALL (a)	3/49 (6%)	1/50 (2%)
LITTERS (b)	3/29 (10%)	1/29 (3%)
POLY-3 RATE (c)	3/40.88	1/41.44
POLY-3 PERCENT (g)	7.3%	2.4%
TERMINAL (d)	3/27 (11%)	1/32 (3%)
FIRST INCIDENCE	744 (T)	744 (T)
STATISTICAL TESTS		
POLY 3		P=0.300N
POLY 1.5		P=0.303N
POLY 6		P=0.289N
RAO-SCOTT		P=0.326N
LITTER C-A/FISHERS		P=0.306N

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Standard Evaluatior Angiectasis	n)		
LESION RATES			
OVERALL (a)	0/49 (0%)	1/50 (2%)	
LITTERS (b)	0/29 (0%)	1/29 (3%)	
POLY-3 RATE (c)	0/40.88	1/41.44	
POLY-3 PERCENT (g)	0%	2.4%	
TERMINAL (d)	0/27 (0%)	1/32 (3%)	
FIRST INCIDENCE		744 (T)	
STATISTICAL TESTS			
POLY 3		P=0.503	
POLY 1.5		P=0.501	
POLY 6		P=0.509	
RAO-SCOTT		P=0.590	
LITTER C-A/FISHERS		P=0.500	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

_		Females
DOSE	0/300 ppm	150/300 ppm
Uterus (Standard or Longitu Angiectasis	udinal Evaluation)	
LESION RATES		
OVERALL (a)	0/49 (0%)	1/50 (2%)
LITTERS (b)	0/29 (0%)	1/29 (3%)
POLY-3 RATE (c)	0/40.88	1/41.44
POLY-3 PERCENT (g)	0%	2.4%
TERMINAL (d)	0/27 (0%)	1/32 (3%)
FIRST INCIDENCE		744 (T)
STATISTICAL TESTS		
POLY 3		P=0.503
POLY 1.5		P=0.501
POLY 6		P=0.509
RAO-SCOTT		P=0.590
LITTER C-A/FISHERS		P=0.500

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
lterus (Longitudinal Evalua ecidual Alteration	ation)		
LESION RATES			
OVERALL (a)	1/49 (2%)	1/50 (2%)	
LITTERS (b)	1/29 (3%)	1/29 (3%)	
POLY-3 RATE (c)	1/40.88	1/41.44	
POLY-3 PERCENT (g)	2.5%	2.4%	
TERMINAL (d)	1/27 (4%)	1/32 (3%)	
FIRST INCIDENCE	744 (T)	744 (T)	
STATISTICAL TESTS			
POLY 3		P=0.758N	
POLY 1.5		P=0.759N	
POLY 6		P=0.752N	
RAO-SCOTT		P=0.724N	
LITTER C-A/FISHERS		P=0.754	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus (Standard or Longitu Decidual Alteration	udinal Evaluation)	
LESION RATES		
OVERALL (a)	1/49 (2%)	1/50 (2%)
LITTERS (b)	1/29 (3%)	1/29 (3%)
POLY-3 RATE (c)	1/40.88	1/41.44
POLY-3 PERCENT (g)	2.5%	2.4%
TERMINAL (d)	1/27 (4%)	1/32 (3%)
FIRST INCIDENCE	744 (T)	744 (T)
STATISTICAL TESTS		
POLY 3		P=0.758N
POLY 1.5		P=0.759N
POLY 6		P=0.752N
RAO-SCOTT		P=0.724N
LITTER C-A/FISHERS		P=0.754

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Standard Evaluatior Dilation	n)		
LESION RATES			
OVERALL (a)	3/49 (6%)	0/50 (0%)	
LITTERS (b)	3/29 (10%)	0/29 (0%)	
POLY-3 RATE (c)	3/41.23	0/41.44	
POLY-3 PERCENT (g)	7.3%	0%	
TERMINAL (d)	2/27 (7%)	0/32 (0%)	
FIRST INCIDENCE	643		
STATISTICAL TESTS			
POLY 3		P=0.117N	
POLY 1.5		P=0.118N	
POLY 6		P=0.113N	
RAO-SCOTT		P=0.188N	
LITTER C-A/FISHERS		P=0.118N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Longitudinal Evalua Dilation	ation)		
LESION RATES			
OVERALL (a)	3/49 (6%)	0/50 (0%)	
LITTERS (b)	3/29 (10%)	0/29 (0%)	
POLY-3 RATE (c)	3/41.23	0/41.44	
POLY-3 PERCENT (g)	7.3%	0%	
TERMINAL (d)	2/27 (7%)	0/32 (0%)	
FIRST INCIDENCE	643		
STATISTICAL TESTS			
POLY 3		P=0.117N	
POLY 1.5		P=0.118N	
POLY 6		P=0.113N	
RAO-SCOTT		P=0.188N	
LITTER C-A/FISHERS		P=0.118N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

_		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Standard or Longitu Dilation	udinal Evaluation)		
LESION RATES			
OVERALL (a)	3/49 (6%)	0/50 (0%)	
LITTERS (b)	3/29 (10%)	0/29 (0%)	
POLY-3 RATE (c)	3/41.23	0/41.44	
POLY-3 PERCENT (g)	7.3%	0%	
TERMINAL (d)	2/27 (7%)	0/32 (0%)	
FIRST INCIDENCE	643		
STATISTICAL TESTS			
POLY 3		P=0.117N	
POLY 1.5		P=0.118N	
POLY 6		P=0.113N	
RAO-SCOTT		P=0.188N	
LITTER C-A/FISHERS		P=0.118N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Longitudinal Evalua Hyperplasia, Atypical	ation)		
LESION RATES			
OVERALL (a)	4/49 (8%)	7/50 (14%)	
LITTERS (b)	4/29 (14%)	6/29 (21%)	
POLY-3 RATE (c)	4/41.02	7/41.44	
POLY-3 PERCENT (g)	9.8%	16.9%	
TERMINAL (d)	3/27 (11%)	7/32 (22%)	
FIRST INCIDENCE	707	744 (T)	
STATISTICAL TESTS			
POLY 3		P=0.264	
POLY 1.5		P=0.262	
POLY 6		P=0.279	
RAO-SCOTT		P=0.290	
LITTER C-A/FISHERS		P=0.365	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus (Standard or Longitı Hyperplasia, Atypical	udinal Evaluation)	
LESION RATES		
OVERALL (a)	4/49 (8%)	7/50 (14%)
LITTERS (b)	4/29 (14%)	6/29 (21%)
POLY-3 RATE (c)	4/41.02	7/41.44
POLY-3 PERCENT (g)	9.8%	16.9%
TERMINAL (d)	3/27 (11%)	7/32 (22%)
FIRST INCIDENCE	707	744 (T)
STATISTICAL TESTS		
POLY 3		P=0.264
POLY 1.5		P=0.262
POLY 6		P=0.279
RAO-SCOTT		P=0.290
LITTER C-A/FISHERS		P=0.365

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females
DOSE	0/300 ppm	150/300 ppm	
Iterus (Standard Evaluation nflammation	n)		
LESION RATES			
OVERALL (a)	1/49 (2%)	3/50 (6%)	
LITTERS (b)	1/29 (3%)	3/29 (10%)	
POLY-3 RATE (c)	1/41.23	3/41.54	
POLY-3 PERCENT (g)	2.4%	7.2%	
TERMINAL (d)	0/27 (0%)	2/32 (6%)	
FIRST INCIDENCE	643	718	
STATISTICAL TESTS			
POLY 3		P=0.307	
POLY 1.5		P=0.306	
POLY 6		P=0.316	
RAO-SCOTT		P=0.323	
LITTER C-A/FISHERS		P=0.306	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus (Standard or Longitun nflammation	udinal Evaluation)	
LESION RATES		
OVERALL (a)	1/49 (2%)	3/50 (6%)
LITTERS (b)	1/29 (3%)	3/29 (10%)
POLY-3 RATE (c)	1/41.23	3/41.54
POLY-3 PERCENT (g)	2.4%	7.2%
TERMINAL (d)	0/27 (0%)	2/32 (6%)
FIRST INCIDENCE	643	718
STATISTICAL TESTS		
POLY 3		P=0.307
POLY 1.5		P=0.306
POLY 6		P=0.316
RAO-SCOTT		P=0.323
LITTER C-A/FISHERS		P=0.306

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Standard Evaluatior Thrombus	1)		
LESION RATES			
OVERALL (a)	1/49 (2%)	0/50 (0%)	
LITTERS (b)	1/29 (3%)	0/29 (0%)	
POLY-3 RATE (c)	1/40.88	0/41.44	
POLY-3 PERCENT (g)	2.5%	0%	
TERMINAL (d)	1/27 (4%)	0/32 (0%)	
FIRST INCIDENCE	744 (T)		
STATISTICAL TESTS			
POLY 3		P=0.497N	
POLY 1.5		P=0.499N	
POLY 6		P=0.491N	
RAO-SCOTT		P=0.589N	
LITTER C-A/FISHERS		P=0.500N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Longitudinal Evalua Thrombus	ation)		
LESION RATES			
OVERALL (a)	1/49 (2%)	0/50 (0%)	
LITTERS (b)	1/29 (3%)	0/29 (0%)	
POLY-3 RATE (c)	1/40.88	0/41.44	
POLY-3 PERCENT (g)	2.5%	0%	
TERMINAL (d)	1/27 (4%)	0/32 (0%)	
FIRST INCIDENCE	744 (T)		
STATISTICAL TESTS			
POLY 3		P=0.497N	
POLY 1.5		P=0.499N	
POLY 6		P=0.491N	
RAO-SCOTT		P=0.589N	
LITTER C-A/FISHERS		P=0.500N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus (Standard or Longitu Thrombus	udinal Evaluation)		
LESION RATES			
OVERALL (a)	1/49 (2%)	0/50 (0%)	
LITTERS (b)	1/29 (3%)	0/29 (0%)	
POLY-3 RATE (c)	1/40.88	0/41.44	
POLY-3 PERCENT (g)	2.5%	0%	
TERMINAL (d)	1/27 (4%)	0/32 (0%)	
FIRST INCIDENCE	744 (T)		
STATISTICAL TESTS			
POLY 3		P=0.497N	
POLY 1.5		P=0.499N	
POLY 6		P=0.491N	
RAO-SCOTT		P=0.589N	
LITTER C-A/FISHERS		P=0.500N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus, Cervix (Standard Ev Hypertrophy	valuation)	
LESION RATES		
OVERALL (a)	1/49 (2%)	1/50 (2%)
LITTERS (b)	1/29 (3%)	1/29 (3%)
POLY-3 RATE (c)	1/40.88	1/41.44
POLY-3 PERCENT (g)	2.5%	2.4%
TERMINAL (d)	1/27 (4%)	1/32 (3%)
FIRST INCIDENCE	744 (T)	744 (T)
STATISTICAL TESTS		
POLY 3		P=0.758N
POLY 1.5		P=0.759N
POLY 6		P=0.752N
RAO-SCOTT		P=0.721N
LITTER C-A/FISHERS		P=0.754

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females
DOSE	0/300 ppm	150/300 ppm	
Uterus, Cervix (Standard or Hypertrophy	Longitudinal Evaluatio	n)	
LESION RATES			
OVERALL (a)	1/49 (2%)	1/50 (2%)	
LITTERS (b)	1/29 (3%)	1/29 (3%)	
POLY-3 RATE (c)	1/40.88	1/41.44	
POLY-3 PERCENT (g)	2.5%	2.4%	
TERMINAL (d)	1/27 (4%)	1/32 (3%)	
FIRST INCIDENCE	744 (T)	744 (T)	
STATISTICAL TESTS			
POLY 3		P=0.758N	
POLY 1.5		P=0.759N	
POLY 6		P=0.752N	
RAO-SCOTT		P=0.721N	
LITTER C-A/FISHERS		P=0.754	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females
DOSE	0/300 ppm	150/300 ppm
Uterus, Cervix (Standard Ev Stromal Hyperplasia	valuation)	
LESION RATES		
OVERALL (a)	0/49 (0%)	1/50 (2%)
LITTERS (b)	0/29 (0%)	1/29 (3%)
POLY-3 RATE (c)	0/40.88	1/41.54
POLY-3 PERCENT (g)	0%	2.4%
TERMINAL (d)	0/27 (0%)	0/32 (0%)
FIRST INCIDENCE		718
STATISTICAL TESTS		
POLY 3		P=0.503
POLY 1.5		P=0.501
POLY 6		P=0.510
RAO-SCOTT		P=0.587
LITTER C-A/FISHERS		P=0.500

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

_		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus, Cervix (Longitudina Stromal Hyperplasia	l Evaluation)		
LESION RATES			
OVERALL (a)	3/49 (6%)	3/50 (6%)	
LITTERS (b)	3/29 (10%)	3/29 (10%)	
POLY-3 RATE (c)	3/40.88	3/41.56	
POLY-3 PERCENT (g)	7.3%	7.2%	
TERMINAL (d)	3/27 (11%)	2/32 (6%)	
FIRST INCIDENCE	744 (T)	714	
STATISTICAL TESTS			
POLY 3		P=0.655N	
POLY 1.5		P=0.659N	
POLY 6		P=0.641N	
RAO-SCOTT		P=0.630N	
LITTER C-A/FISHERS		P=0.665	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
Uterus, Cervix (Standard or	Longitudinal Evaluation	n)		
Stromal Hyperplasia				
LESION RATES				
OVERALL (a)	3/49 (6%)	4/50 (8%)		
LITTERS (b)	3/29 (10%)	4/29 (14%)		
POLY-3 RATE (c)	3/40.88	4/41.66		
POLY-3 PERCENT (g)	7.3%	9.6%		
TERMINAL (d)	3/27 (11%)	2/32 (6%)		
FIRST INCIDENCE	744 (T)	714		
STATISTICAL TESTS				
POLY 3		P=0.510		
POLY 1.5		P=0.504		
POLY 6		P=0.530		
RAO-SCOTT		P=0.487		
LITTER C-A/FISHERS		P=0.500		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
Utamia Camin Enith - lines (.		
Uterus, Cervix, Epithelium (Basal Cell Hyperplasia	Longitudinal Evaluation	1)		
LESION RATES				
OVERALL (a)	4/49 (8%)	6/50 (12%)		
LITTERS (b)	4/29 (14%)	5/29 (17%)		
POLY-3 RATE (c)	4/41.13	6/41.54		
POLY-3 PERCENT (g)	9.7%	14.4%		
TERMINAL (d)	3/27 (11%)	5/32 (16%)		
FIRST INCIDENCE	676	718		
STATISTICAL TESTS				
POLY 3		P=0.375		
POLY 1.5		P=0.371		
POLY 6		P=0.391		
RAO-SCOTT		P=0.391		
LITTER C-A/FISHERS		P=0.500		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
Uterus, Cervix, Epithelium ((Standard or Longitudin	al Evaluation)		
Basal Cell Hyperplasia				
LESION RATES				
OVERALL (a)	4/49 (8%)	6/50 (12%)		
LITTERS (b)	4/29 (14%)	5/29 (17%)		
POLY-3 RATE (c)	4/41.13	6/41.54		
POLY-3 PERCENT (g)	9.7%	14.4%		
TERMINAL (d)	3/27 (11%)	5/32 (16%)		
FIRST INCIDENCE	676	718		
STATISTICAL TESTS				
POLY 3		P=0.375		
POLY 1.5		P=0.371		
POLY 6		P=0.391		
RAO-SCOTT		P=0.391		
LITTER C-A/FISHERS		P=0.500		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus, Endometrium (Stan Hyperplasia	dard Evaluation)		
LESION RATES			
OVERALL (a)	1/49 (2%)	0/50 (0%)	
LITTERS (b)	1/29 (3%)	0/29 (0%)	
POLY-3 RATE (c)	1/41.02	0/41.44	
POLY-3 PERCENT (g)	2.4%	0%	
TERMINAL (d)	0/27 (0%)	0/32 (0%)	
FIRST INCIDENCE	707		
STATISTICAL TESTS			
POLY 3		P=0.498N	
POLY 1.5		P=0.499N	
POLY 6		P=0.493N	
RAO-SCOTT		P=0.587N	
LITTER C-A/FISHERS		P=0.500N	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
Uterus, Endometrium (Stan	dard or Longitudinal Ev	valuation)		
Hyperplasia		aluationy		
LESION RATES				
OVERALL (a)	1/49 (2%)	0/50 (0%)		
LITTERS (b)	1/29 (3%)	0/29 (0%)		
POLY-3 RATE (c)	1/41.02	0/41.44		
POLY-3 PERCENT (g)	2.4%	0%		
TERMINAL (d)	0/27 (0%)	0/32 (0%)		
FIRST INCIDENCE	707			
STATISTICAL TESTS				
POLY 3		P=0.498N		
POLY 1.5		P=0.499N		
POLY 6		P=0.493N		
RAO-SCOTT		P=0.587N		
LITTER C-A/FISHERS		P=0.500N		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
terus, Endometrium (Stan yperplasia, Cystic	dard Evaluation)			
LESION RATES				
OVERALL (a)	22/49 (45%)	31/50 (62%)		
LITTERS (b)	17/29 (59%)	22/29 (76%)		
POLY-3 RATE (c)	22/43.15	31/45.18		
POLY-3 PERCENT (g)	51%	68.6%		
TERMINAL (d)	14/27 (52%)	22/32 (69%)		
FIRST INCIDENCE	484	322		
STATISTICAL TESTS				
POLY 3		P=0.064		
POLY 1.5		P=0.056		
POLY 6		P=0.089		
RAO-SCOTT		P=0.093		
LITTER C-A/FISHERS		P=0.131		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

_			Females	
DOSE	0/300 ppm	150/300 ppm		
terus, Endometrium (Long yperplasia, Cystic	itudinal Evaluation)			
LESION RATES				
OVERALL (a)	27/49 (55%)	36/50 (72%)		
LITTERS (b)	19/29 (66%)	25/29 (86%)		
POLY-3 RATE (c)	27/44.15	36/47.07		
POLY-3 PERCENT (g)	61.2%	76.5%		
TERMINAL (d)	17/27 (63%)	24/32 (75%)		
FIRST INCIDENCE	470	322		
STATISTICAL TESTS				
POLY 3		P=0.080		
POLY 1.5		P=0.066		
POLY 6		P=0.115		
RAO-SCOTT		P=0.119		
LITTER C-A/FISHERS		P=0.062		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
Uterus, Endometrium (Stan	dard or Longitudinal Eva	luation)		
Hyperplasia, Cystic	-			
LESION RATES				
OVERALL (a)	27/49 (55%)	36/50 (72%)		
LITTERS (b)	19/29 (66%)	25/29 (86%)		
POLY-3 RATE (c)	27/44.15	36/47.07		
POLY-3 PERCENT (g)	61.2%	76.5%		
TERMINAL (d)	17/27 (63%)	24/32 (75%)		
FIRST INCIDENCE	470	322		
STATISTICAL TESTS				
POLY 3		P=0.080		
POLY 1.5		P=0.066		
POLY 6		P=0.115		
RAO-SCOTT		P=0.119		
LITTER C-A/FISHERS		P=0.062		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Uterus, Endometrium (Stan Metaplasia	dard Evaluation)		
LESION RATES			
OVERALL (a)	17/49 (35%)	21/50 (42%)	
LITTERS (b)	15/29 (52%)	16/29 (55%)	
POLY-3 RATE (c)	17/43.75	21/43.55	
POLY-3 PERCENT (g)	38.9%	48.2%	
TERMINAL (d)	9/27 (33%)	17/32 (53%)	
FIRST INCIDENCE	470	322	
STATISTICAL TESTS			
POLY 3		P=0.250	
POLY 1.5		P=0.257	
POLY 6		P=0.260	
RAO-SCOTT		P=0.259	
LITTER C-A/FISHERS		P=0.500	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
lterus, Endometrium (Long letaplasia, Squamous	itudinal Evaluation)			
LESION RATES				
OVERALL (a)	19/49 (39%)	25/50 (50%)		
LITTERS (b)	17/29 (59%)	20/29 (69%)		
POLY-3 RATE (c)	19/43.75	25/44.60		
POLY-3 PERCENT (g)	43.4%	56.1%		
TERMINAL (d)	11/27 (41%)	19/32 (59%)		
FIRST INCIDENCE	470	322		
STATISTICAL TESTS				
POLY 3		P=0.160		
POLY 1.5		P=0.157		
POLY 6		P=0.183		
RAO-SCOTT		P=0.159		
LITTER C-A/FISHERS		P=0.293		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females	
DOSE	0/300 ppm	150/300 ppm		
lterus, Endometrium (Stand Ietaplasia, Squamous or M		aluation)		
LESION RATES				
OVERALL (a)	19/49 (39%)	25/50 (50%)		
LITTERS (b)	17/29 (59%)	20/29 (69%)		
POLY-3 RATE (c)	19/43.75	25/44.60		
POLY-3 PERCENT (g)	43.4%	56.1%		
TERMINAL (d)	11/27 (41%)	19/32 (59%)		
FIRST INCIDENCE	470	322		
STATISTICAL TESTS				
POLY 3		P=0.160		
POLY 1.5		P=0.157		
POLY 6		P=0.183		
RAO-SCOTT		P=0.159		
LITTER C-A/FISHERS		P=0.293		

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

			Females
DOSE	0/300 ppm	150/300 ppm	
Uterus, Endometrial Glands	(Longitudinal Evaluatio	on)	
Hyperplasia			
LESION RATES			
OVERALL (a)	2/49 (4%)	5/50 (10%)	
LITTERS (b)	2/29 (7%)	5/29 (17%)	
POLY-3 RATE (c)	2/41.32	5/41.44	
POLY-3 PERCENT (g)	4.8%	12.1%	
TERMINAL (d)	0/27 (0%)	5/32 (16%)	
FIRST INCIDENCE	659	744 (T)	
STATISTICAL TESTS			
POLY 3		P=0.216	
POLY 1.5		P=0.216	
POLY 6		P=0.223	
RAO-SCOTT		P=0.237	
LITTER C-A/FISHERS		P=0.211	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

DOSE	0/300 ppm	150/300 ppm
Uterus, Endometrial Glands	s (Standard or Longitudi	inal Evaluation)
Hyperplasia		
LESION RATES		
OVERALL (a)	2/49 (4%)	5/50 (10%)
LITTERS (b)	2/29 (7%)	5/29 (17%)
POLY-3 RATE (c)	2/41.32	5/41.44
POLY-3 PERCENT (g)	4.8%	12.1%
TERMINAL (d)	0/27 (0%)	5/32 (16%)
FIRST INCIDENCE	659	744 (T)
STATISTICAL TESTS		
POLY 3		P=0.216
POLY 1.5		P=0.216
POLY 6		P=0.223
RAO-SCOTT		P=0.237
LITTER C-A/FISHERS		P=0.211

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
Vagina (Longitudinal Evalua Hyperplasia, Granular Cell	ation)		
LESION RATES			
OVERALL (a)	7/49 (14%)	0/50 (0%)	
LITTERS (b)	6/29 (21%)	0/29 (0%)	
POLY-3 RATE (c)	7/41.39	0/41.44	
POLY-3 PERCENT (g)	16.9%	0%	
TERMINAL (d)	4/27 (15%)	0/32 (0%)	
FIRST INCIDENCE	659		
STATISTICAL TESTS			
POLY 3		P=0.007N**	
POLY 1.5		P=0.007N**	
POLY 6		P=0.006N**	
RAO-SCOTT		P=0.035N*	
LITTER C-A/FISHERS		P=0.012N*	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

		Females	
DOSE	0/300 ppm	150/300 ppm	
/agina (Standard or Longitı Iyperplasia, Granular Cell	udinal Evaluation)		
LESION RATES			
OVERALL (a)	7/49 (14%)	0/50 (0%)	
LITTERS (b)	6/29 (21%)	0/29 (0%)	
POLY-3 RATE (c)	7/41.39	0/41.44	
POLY-3 PERCENT (g)	16.9%	0%	
TERMINAL (d)	4/27 (15%)	0/32 (0%)	
FIRST INCIDENCE	659		
STATISTICAL TESTS			
POLY 3		P=0.007N**	
POLY 1.5		P=0.007N**	
POLY 6		P=0.006N**	
RAO-SCOTT		P=0.035N*	
LITTER C-A/FISHERS		P=0.012N*	

Perfluorooctanoic Acid **CAS Number:** 335-67-1

Date Report Requested: 03/10/2022 Time Report Requested: 10:51:55 First Dose M/F: 10/27/08 / 10/28/08 Lab: BAT

LEGEND

Number of tumor-bearing animals/number of animals examined at site. (a) (b) Number of litters with tumor-bearing animals/number of litters examined at site (c) Number of tumor-bearing animals/Poly-3 number (d) Observed incidence at terminal kill. (e) Value of statistic cannot be computed. Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to (f) pairwise comparisons between the controls and that dosed group. Poly-3 adjusted lifetime tumor incidence. (g) (I) Interim sacrifice Terminal sacrifice (T) Tumor rates based on numbers of animals necropsied. To the right of any statistical result, indicates significance at (P<=0.05). ** To the right of any statistical result, indicates significance at (P<=0.01). Ν Indicates a negative trend for all tests The Rao-Scott statistic performs the Poly-3 test with an adjustment for within-litter correlation. The Litter C-A/Fishers statistic compares directly the litter incidence rates.

*** END OF REPORT ***